+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Bacterial Pneumonia - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 180 Pages
  • November 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6294581
The bacterial pneumonia market is expected to grow from USD 7.50 billion in 2026 to USD 7.88 billion in 2027 and is forecasted to reach USD 10.61 billion by 2032 at a 6.13% CAGR over 2027-2032. This report is Segmented by Infection Type (Community-Acquired Bacterial Pneumonia, and More), Diagnosis & Treatment (Diagnosis, Treatment), Pathogen Type (Streptococcus Pneumoniae, and More), Age Group (Infants, Children, and More), End-User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Bacterial Pneumonia Market Trends and Insights

Aging Population and Higher Pneumonia Risk

Population aging is a durable source of demand in the bacterial pneumonia market. Adults aged 65 years and older had an annual pneumonia incidence of 25 to 44 cases per 1,000 people, compared with 6 to 10 cases among adults aged 18 to 64 years. Older patients often require longer hospital stays, more complex antibiotic regimens, and more intensive monitoring. These care needs raise the value of each treated episode for hospitals, pharmacies, and diagnostic providers. A study of 4,515 hospitalized older adults with community-acquired pneumonia found that prior pneumococcal vaccination reduced 30-day mortality by 42%. Japanese guidance has also placed greater emphasis on nursing-home-acquired pneumonia, reflecting the clinical needs of a super-aging population.

Expansion of Pneumococcal Immunization Programs and Serotype Surveillance

Expanded vaccination schedules are widening the prevention opportunity in the bacterial pneumonia market. U.S. recommendations now include pneumococcal conjugate vaccination for adults aged 50 years and older who have not previously received a pneumococcal conjugate vaccine. This policy broadens access beyond the earlier age-based approach for adults aged 65 years and older. Vaccine use can reduce disease caused by covered serotypes, but it also increases the need to monitor replacement by other serotypes. Belgian surveillance found that serotype 12F represented 19.6% of invasive pneumococcal disease isolates in 2025, up from 14.6% in 2024. This pattern supports continued development of higher-valency vaccines and makes surveillance an important part of product planning.

Antimicrobial Stewardship Restricting Broad-Spectrum Antibiotic Use

Antimicrobial stewardship limits unnecessary use of broad-spectrum antibiotics in the bacterial pneumonia market. The INSPIRE trial covered 59 hospitals and 44,780 adult patients and found that prescribing prompts reduced empiric extended-spectrum antibiotic use by 28.4%. The trial did not find higher intensive care transfers or longer hospital stays. A 2026 meta-analysis of 19 studies found that stewardship shortened antibiotic duration and improved protocol adherence without compromising mortality. These programs reduce sales of older generic therapies. They can still support the use of novel agents when a resistant pathogen has been identified, and a narrow treatment choice is clinically justified.

Other drivers and restraints analyzed in the detailed report include:

  1. Rising Hospital-Acquired and Ventilator-Associated Pneumonia Burden
  2. Demand for Rapid Pathogen Identification and Targeted Therapy
  3. Limited Treatment Access, Reimbursement, and Surveillance Infrastructure

Segment Analysis

Community-acquired bacterial pneumonia held 52.15% of the bacterial pneumonia market share in 2026. Its scale reflects its prevalence across outpatient care, general wards, vaccination programs, diagnostics, and antibiotic treatment. Updated American Thoracic Society guidance supports lung ultrasound as an alternative diagnostic approach in suitable cases and shorter antibiotic courses for clinically stable patients. Shorter courses can reduce the volume of conventional treatment while maintaining demand for diagnostics and therapies directed at resistant organisms.

Hospital-acquired bacterial pneumonia is forecasted to expand at 7.17% CAGR through 2032. Ventilator-associated cases are particularly important because they are associated with greater clinical severity and resource use. Pipeline work in hospital- and ventilator-associated disease remains active, showing that companies view this niche as clinically and commercially important. The bacterial pneumonia market continues to favor therapies that address resistant pathogens in the most acute hospital settings.

Diagnosis captured 53.41% of the bacterial pneumonia market size in 2026. Molecular platforms are gaining use in complex inpatient cases because they identify pathogens and resistance markers faster than conventional culture. A United Kingdom research program found that appropriate empiric therapy was received by only 46.5% of hospital-acquired and ventilator-associated pneumonia patients. This gap explains why hospitals are adopting tests that can guide therapy earlier. Pulse oximetry remains a common bedside tool for severity assessment, while molecular panels are becoming more important for complex infections.

Treatment is expected to grow at an 8.23% CAGR through 2032, making it the fastest-growing component. Antibiotics remain the main revenue source, but treatment value is shifting toward targeted and premium products. Paratek reported an 89.6% clinical success rate for omadacycline in its Phase 3b OPTIC-2 study of moderate-to-severe community-acquired bacterial pneumonia. Oxygen therapy, hospitalization, and supportive care continue to grow with case volume. Therapy selection increasingly depends on pathogen and resistance information. This creates a closer link between the treatment and diagnosis components.

Complete Report Scope:

  • By Infection Type
    • Community-Acquired Bacterial Pneumonia
    • Hospital-Acquired Bacterial Pneumonia
    • Ventilator-Associated Bacterial Pneumonia
  • By Diagnosis & Treatment
    • Diagnosis
      • Chest X-Ray
      • CT Scan
      • Sputum Culture
      • Blood Tests
      • Pulse Oximetry
    • Treatment
      • Antibiotics
      • Oxygen Therapy
      • Supportive Care
  • By Pathogen Type
    • Streptococcus pneumoniae
    • Haemophilus influenzae
    • Staphylococcus aureus
    • Escherichia coli
    • Other Pathogen Types
  • By Age Group
    • Infants
    • Children
    • Adults
    • Geriatric Population
  • By End-User
    • Hospitals
    • Intensive Care Units
    • Diagnostic Laboratories
    • Other End-Users
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 47.24% of regional revenue in 2026. The United States recorded 41,627 pneumonia deaths in 2024 and 1.2 million emergency department visits annually. Adult vaccine recommendations now cover eligible vaccine-naive adults aged 50 years and older. This policy enlarges the prevention pool for pneumococcal disease. Mature reimbursement and hospital distribution systems support pricing for molecular diagnostics and newer antibiotics.

Europe is characterized by differing ventilator-associated pneumonia rates, established stewardship programs, and changing serotype patterns. A 2026 analysis of German data reported a resurgence of PCV13 serotypes, persistent serotype 3, and an increase in serotype 38 during 2023 and 2024. These patterns complicate decisions around vaccine composition and program design. NICE guidance provides a common clinical framework in the United Kingdom, including pediatric protocols updated in 2025. Germany, the United Kingdom, France, Italy, and Spain remain the largest European demand centers.

Asia-Pacific is projected to grow at a 10.33% CAGR through 2032, the fastest regional rate in the bacterial pneumonia market. India has 5 to 11 community-acquired pneumonia cases per 1,000 people each year and accounts for 23% of the global burden. South Korea added PCV20 to its national immunization program in October 2025, while Japan has updated pneumonia guidance for its aging population. The Middle East and Africa face cold-chain and reimbursement barriers, although the Gulf Cooperation Council health investment and South Africa’s private diagnostics network create entry points. South America is supported by vaccine program completion and improving urban antibiotic access, especially in Brazil and Argentina.



List of Companies Covered in this Report:

  1. Abbott Laboratories
  2. AstraZeneca
  3. Aurobindo Pharma
  4. Basilea Pharmaceutica Ltd.
  5. Bayer
  6. bioMérieux
  7. Clarametyx Biosciences, Inc.
  8. Roche
  9. GlaxoSmithKline
  10. Innoviva, Inc.
  11. Lupin
  12. Melinta Therapeutics, LLC
  13. Merck
  14. Novartis
  15. Paratek Pharmaceuticals
  16. Pfizer
  17. Sanofi
  18. Shionogi & Co., Ltd.
  19. Vaxcyte, Inc.
  20. Wockhardt Limited

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Aging Population and Higher Pneumonia Risk
4.2.2 Expansion of Pneumococcal Immunization Programs
4.2.3 Rising Hospital-Acquired and Ventilator-Associated Pneumonia Burden
4.2.4 Demand for Rapid Pathogen Identification and Targeted Therapy
4.2.5 Growth of Novel Antibacterial Therapies for Multidrug-Resistant Pathogens
4.2.6 Serotype Replacement and Non-Vaccine Serotype Surveillance
4.3 Market Restraints
4.3.1 Antimicrobial Stewardship Restricting Broad-Spectrum Antibiotic Use
4.3.2 Limited Treatment Access and Weak Healthcare Infrastructure in Low-Income Markets
4.3.3 Diagnostic Reimbursement Gaps for Multiplex Molecular Testing
4.3.4 Fragmented Serotype and Resistance Surveillance in Emerging Markets
4.4 Supply/Value Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Infection Type
5.1.1 Community-Acquired Bacterial Pneumonia
5.1.2 Hospital-Acquired Bacterial Pneumonia
5.1.3 Ventilator-Associated Bacterial Pneumonia
5.2 By Diagnosis & Treatment
5.2.1 Diagnosis
5.2.1.1 Chest X-Ray
5.2.1.2 CT Scan
5.2.1.3 Sputum Culture
5.2.1.4 Blood Tests
5.2.1.5 Pulse Oximetry
5.2.2 Treatment
5.2.2.1 Antibiotics
5.2.2.2 Oxygen Therapy
5.2.2.3 Supportive Care
5.3 By Pathogen Type
5.3.1 Streptococcus pneumoniae
5.3.2 Haemophilus influenzae
5.3.3 Staphylococcus aureus
5.3.4 Escherichia coli
5.3.5 Other Pathogen Types
5.4 By Age Group
5.4.1 Infants
5.4.2 Children
5.4.3 Adults
5.4.4 Geriatric Population
5.5 By End-User
5.5.1 Hospitals
5.5.2 Intensive Care Units
5.5.3 Diagnostic Laboratories
5.5.4 Other End-Users
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
6.3.1 Abbott Laboratories
6.3.2 AstraZeneca PLC
6.3.3 Aurobindo Pharma Limited
6.3.4 Basilea Pharmaceutica Ltd.
6.3.5 Bayer AG
6.3.6 bioMerieux SA
6.3.7 Clarametyx Biosciences, Inc.
6.3.8 F. Hoffmann-La Roche Ltd
6.3.9 GSK plc
6.3.10 Innoviva, Inc.
6.3.11 Lupin Limited
6.3.12 Melinta Therapeutics, LLC
6.3.13 Merck & Co., Inc.
6.3.14 Novartis AG
6.3.15 Paratek Pharmaceuticals, Inc.
6.3.16 Pfizer Inc.
6.3.17 Sanofi
6.3.18 Shionogi & Co., Ltd.
6.3.19 Vaxcyte, Inc.
6.3.20 Wockhardt Limited
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • bioMerieux SA
  • Clarametyx Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Innoviva, Inc.
  • Lupin Limited
  • Melinta Therapeutics, LLC
  • Merck & Co., Inc.
  • Novartis AG
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Sanofi
  • Shionogi & Co., Ltd.
  • Vaxcyte, Inc.
  • Wockhardt Limited